{"contentid": 488006, "importid": NaN, "name": "End to GSK losing streak brings hope for COVID-19 patients", "introduction": "Positive Phase III data herald a significant turnaround in the fortunes of GlaxoSmithKline\u00e2\u0080\u0099s coronavirus program.", "content": "<p>Positive Phase III data herald a significant turnaround in the fortunes of GlaxoSmithKline&rsquo;s (LSE: GSK) coronavirus program.</p>\n<p>Data monitors have recommended halting the COMET-ICE study due to strong efficacy, with an 85% reduction in hospitalization or death in people receiving VIR-7831 as monotherapy, compared to placebo.</p>\n<p>Together with Vir Biotechnology (Nasdaq: VIR), GSK is testing the monoclonal antibody as an early treatment for COVID-19 in adults at high risk of hospitalization.</p>\n<p>The trial hit was not entirely expected, after enrollment in the separate, National Institutes of Health (NIH)-led ACTIV study was stopped due to unclear benefit at the start of March.</p>\n<p>That event sent Vir stock tumbling over a quarter, while news from the COMET-ICE result boosted the firm&rsquo;s share price by a similar amount in pre-market trading on Thursday.</p>\n<h2>Change in fortunes</h2>\n<p>Based on the data, which also show the biologic was generally well tolerated, the firms will now submit for an Emergency Use Authorization (EUA) in the USA.</p>\n<p>Formal marketing authorization submissions will also be made in the USA and in other countries, while additional results, including epidemiology and virology data, are forthcoming.</p>\n<p>The companies have also announced the results of a new pre-clinical study, pending online publication in bioRxiv, showing that VIR-7831 maintains activity against current circulating variants of concern including the UK, South African and Brazilian variants.</p>\n<p>Vir chief executive George Scangos said: \"The dual-action design of VIR-7831 to both block viral entry into healthy cells and clear infected cells, as well as its high barrier to resistance, are key distinguishing characteristics.&rdquo;</p>\n<p>GSK chief scientific officer Hal Barron said: \"We are pleased that this unique monoclonal antibody was able to bring such a profound benefit to patients. We look forward to the possibility of making VIR-7831 available to patients as soon as possible and to further exploring its potential in other settings.\"</p>", "date": "2021-03-11 10:27:00", "meta_title": NaN, "meta_keywords": "data, fortunes, patients, COVID-, losing, VIR-, streak, brings, hope, Phase, study, herald, significant, turnaround, coronavirus, program, Positive, strong", "meta_description": "Positive Phase III data herald a significant turnaround in the fortunes of GlaxoSmithKline\u00e2\u0080\u0099s coronavirus program.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-11 09:36:45", "updated": "2021-03-11 10:27:16", "access": NaN, "url": "https://www.thepharmaletter.com/article/end-to-gsk-losing-streak-brings-hope-for-covid-19-patients", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "glaxo_gsk_glaxosmithkline_big.jpg", "image2id": "glaxo_gsk_glaxosmithkline_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-virals, Infectious diseases", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "UK, USA", "company_tag": "GlaxoSmithKline, Vir Biotechnology", "drug_tag": "VIR-7831", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-11 10:27:00"}